Abstract: Implantable depots for the sustained, controlled release of therapeutic agents, and associated systems and methods, are disclosed herein. In some embodiments, for example, an implantable depot for treating pain includes an analgesic constituting at least 50% of a total mass of the implantable depot. At least some or all of the analgesic can be in a free base form. When implanted at a treatment site in vivo, the implantable depot can be configured to release the analgesic over a release period of at least 3 days.

Abstract: The devices, systems, and methods disclosed herein may be directed to a delivery system including a therapeutic member configured for endoluminal placement via the delivery system into the esophagus of the patient, wherein the therapeutic member comprises a treatment portion comprising a film for controlled release of a chemotherapeutic agent. The film may comprise a control region, a therapeutic region, and a substantially impermeable base region. The film is configured to release the chemotherapeutic agent in a direction away from the substantially impermeable base region. The delivery system is configured to enable a treatment provider to position the treatment portion of the therapeutic member proximate to a treatment site associated with the esophagus of the patient, and the therapeutic member is configured to administer a therapeutically effective dose to the treatment site for a sustained period following endoluminal placement of the therapeutic member.

Abstract: The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Abstract: Implantable depots for delivering therapeutic agents and associated systems and methods are provided. In some embodiments, an implantable depot for treating pain in a subject after a surgical procedure includes a therapeutic region having a first polymer and an analgesic agent, a first control region including a second polymer, and a second control region including a third polymer. The first and second control regions can cover first and second surfaces of the therapeutic region to inhibit release of the analgesic agent therefrom. The depot can include one or more holes extending through the first and second control regions and the therapeutic region to form one or more exposed portions. When implanted in the subject, the implantable depot can release the analgesic agent from a lateral surface of the therapeutic region between the first and second surfaces, and from the exposed portions of the therapeutic region.

Abstract: The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Abstract: Systems and processes for the production of lithium metal from molten salts. Systems can include a ceramic tube affixed by or to a freeze-composite. The freeze-composite includes a matrix, of a salt and a dispersed phase. The freeze is maintained with a cooling collar to maintain a temperature below the melting point of the salt. Systems can include a molten-catholyte and a molten-anolyte each adjacent to separate surfaces of the ceramic tube. The freeze-composite forms a fluidic and non-conductive barrier between the molten-catholyte and the molten-anolyte. Processes include a freeze-composite affixed to the ceramic tube. The ceramic tube is adjacent to a composite collar which is adjacent to a cooling collar; The cooling fluid is passed through the cooling collar. A molten-catholyte is passed along a first surface of the ceramic tube. A molten-anolyte is passed along to a second surface of the ceramic tube.

Abstract: Systems and processes for the production of lithium metal from molten salts. Systems can include a ceramic tube affixed by or to a freeze-composite. The freeze-composite includes a matrix, of a salt and a dispersed phase. The freeze is maintained with a cooling collar to maintain a temperature below the melting point of the salt. Systems can include a molten-catholyte and a molten-anolyte each adjacent to separate surfaces of the ceramic tube. The freeze-composite forms a fluidic and non-conductive barrier between the molten-catholyte and the molten-anolyte. Processes include a freeze-composite affixed to the ceramic tube. The ceramic tube is adjacent to a composite collar which is adjacent to a cooling collar; The cooling fluid is passed through the cooling collar. A molten-catholyte is passed along a first surface of the ceramic tube. A molten-anolyte is passed along to a second surface of the ceramic tube.

Abstract: The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Abstract: The present technology relates to polymer implants. In some embodiments, the polymer implant may have a volume having minimum cross-sectional dimension of 400 ?m. The polymer implant may be configured to be implanted within a mammalian body for at least 3 days without undergoing core acidification.

Abstract: An implantable light delivery device comprises: a core portion cladded in a cladding, the core portion comprising upconversion nano-particles (UCNPs) encapsulated in an encapsulation material. The implantable light delivery device may be used in treatments such as photodynamic therapy to provide an emission of light at a wavelength configured by the selection of UCNPs. The encapsulation material may comprise hydrogel and the cladding may comprise fluorinated ethylene propylene.

Abstract: The present technology relates to implantable depots for the local, sustained, controlled release of a therapeutic agent to treat cancer. An implantable depot may comprise a biodegradable polymer mixed with a locally-acting therapeutic agent configured to treat cancer. The depot may be configured to be implanted within a patient proximate cancerous tissue and, while implanted, provide sustained exposure of the therapeutic agent at the treatment site for a period of time that is no less than 5 days.

Abstract: The present technology relates to depots for the treatment of select symptoms via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising the therapeutic agent, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for an extended period of time.

Abstract: The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Abstract: The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Abstract: The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Abstract: The present technology relates to depot assemblies for the controlled, sustained release of a therapeutic agent. The assembly can include a depot having a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days. The assembly further includes a fixation portion coupled to the depot and configured to facilitate attachment of the depot assembly to tissue at or adjacent to the treatment site.

Abstract: The present technology relates to polymer implants. In some embodiments, the polymer implant may have a volume having minimum cross-sectional dimension of 400 ?m. The polymer implant may be configured to be implanted within a mammalian body for at least 3 days without undergoing core acidification.

Abstract: Provided herein are compositions of virus like particles (VLPs) of poliovirus (PV) that have one or more stabilizing mutations that confer a higher degree of thermostability to the N-antigenic form of the VLPs. These VLPs are non-infectious, and thus safer for use in vaccine development and administration to clinical subjects.

Abstract: The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Abstract: The present technology relates to depot assemblies for the controlled, sustained release of a therapeutic agent. The assembly can include a depot having a therapeutic region comprising a therapeutic agent, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.